Finance

Beta
Lists
ISI:FRA
Ionis Pharmaceuticals Inc
€63.94
+1.49%
(+0.94) 1D
Jun 5, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ISI...
Open
€63.94
High
€63.94
Low
€63.94
Mkt. cap
12.31B
Avg. vol.
25.00
Volume
0.00
52-wk high
€72.60
52-wk low
€30.18
No. of employees
1K
Open
€63.94
High
€63.94
Low
€63.94
Mkt. cap
12.31B
Avg. vol.
25.00
Volume
0.00
52-wk high
€72.60
52-wk low
€30.18
No. of employees
1K
News stories
From sources across the web
Profile
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015. Wikipedia
About Ionis Pharmaceuticals Inc
CEOBrett P. Monia Ph.D.
Employees1.4K
Founded1989
HeadquartersCarlsbad, California, United States
SectorBiotechnology
Websiteionis.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
452.05M
156.72M
203.33M
246.09M
Cost of goods sold
221.61M
220.09M
287.60M
213.16M
Cost of revenue
221.61M
220.09M
287.60M
213.16M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
90.62M
96.81M
130.19M
150.36M
Operating expense
90.62M
96.81M
130.19M
150.36M
Total operating expenses
312.23M
316.90M
417.79M
363.52M
Operating income
139.82M
-160.18M
-214.46M
-117.42M
Other non operating income
102.00K
363.00K
57.00K
-456.00K
EBT including unusual items
123.53M
-128.39M
-227.92M
-92.31M
EBT excluding unusual items
141.84M
-158.30M
-212.36M
-114.89M
Income tax expense
-20.00K
213.00K
1.48M
218.00K
Effective tax rate
-0.02%
-0.17%
-0.65%
-0.24%
Other operating expenses
-
-
-
-
Net income
123.55M
-128.61M
-229.39M
-92.53M
Net profit margin
27.33%
-82.06%
-112.82%
-37.60%
Earnings per share
0.85
-0.61
-1.15
-0.30
Interest and investment income
24.69M
23.68M
24.73M
25.48M
Interest expense
-22.76M
-22.16M
-22.69M
-22.50M
Net interest expenses
1.92M
1.52M
2.04M
2.99M
Depreciation and amortization charges
-
-
-
-
EBITDA
142.68M
-157.31M
-210.56M
-113.46M
Gain or loss from assets sale
236.00K
-3.94M
638.00K
40.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer